Alere i Influenza A & B Product Usage: The Alere i Influenza A and B assay
Recall Z-1677-2015, part of FDA recall event 71059. See Alere Scarborough's company page.
Alere Scarborough, Inc. dba Binax, Inc. started this Class II device recall on Apr 22, 2015 (voluntary: firm initiated); FDA lists it as terminated, terminated Jan 14, 2016.
- Classification: Class II
- Started: Apr 22, 2015
- Status: Terminated
High invalid rate and an increased risk of false negative results with certain lots of the Alere i Influenza A & B kit.
- Product
- Alere i Influenza A & B Product Usage: The Alere i Influenza A and B assay, performed on the Alere i Instrument, is a rapid molecular in vitro diagnostic test utilizing an isothermal nucleic acid amplification technology for the qualitative detection and discrimination of influenza A and B viral RNA in nasal swabs from patients with signs and symptoms of respiratory infection. It is intended for use as an aid in the differential diagnosis of influenza A and B viral infections in humans, in conjunction with clinical and epidemiological risk factors. The assay is not intended to detect the presence of influenza C virus.
- Quantity
- 213 kits plus 3 - evaluation use only kits
- Lots and codes
- PN 425-024, LN 0072633 (United States Distribution) and PN 425-000, LN 0073888 (distributed in Hong Kong, Singapore - evaluation use only)
- Distribution
- Worldwide Distribution - US Nationwide in the states of AL CA CT FL IA ID IL IN KY LA MD MO MS NC NE NJ OH PA SC TN TX and the countries of: Hong Kong and Singapore.
- Recalling firm
- Alere Scarborough, Inc. dba Binax, Inc., Scarborough, ME, United States
- How the firm notified
- Letter
- FDA classified
- May 27, 2015
Newest first, one product per recall event; search them all
- Alere i flu, Alere i, Alere Influenza A & B; Part Number (PN) 425-024 The Alere" i Influenza A & B assay, performed on…Z-2095-2015 · Class II · Jun 26, 2015 · Terminated
FDA's weekly Enforcement Report, as openFDA publishes it. A recall is classified by how likely the product is to cause harm: Class I is the most serious. openFDA device enforcement reports